[Skip to Navigation]
Special Communication
March 4, 2019

Chemotherapy and Supportive Care Agents as Essential Medicines for Children With Cancer

Author Affiliations
  • 1Division of Pediatric Hematology-Oncology, The Herman and Walter Samuelson Children’s Hospital at Sinai, Baltimore, Maryland
  • 2Johns Hopkins University, Berman Institute of Bioethics, Baltimore, Maryland
  • 3Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
  • 4Texas Children’s Cancer Center, Baylor College of Medicine, Houston, Texas
  • 5St Jude Children’s Research Hospital, Memphis, Tennessee
  • 6Bass Center for Childhood Cancer and Blood Diseases, Lucile Packard Children’s Hospital, Stanford, California
  • 7University of Iowa, Iowa City
  • 8Pediatric Hematology-Oncology, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada
JAMA Pediatr. 2019;173(5):477-484. doi:10.1001/jamapediatrics.2019.0070

In resource-rich countries, 5-year survival rates for children with cancer approach 85%. This impressive statistic is largely the result of integrating research with clinical care. At the core of this endeavor are multiagent combination chemotherapy and supportive care agents (CASCA). Most CASCAs belong to the class of sterile injectable drugs, which make up the backbone of many proven and life-saving pediatric oncology regimens. There are few if any alternative agents available to treat most life-threatening childhood cancers. In the United States, shortages of CASCAs are now commonplace. The consequences of drug shortages are far reaching. Beyond the economic costs, these shortages directly affect patients’ lives, and this is especially true for children with cancer. Drug shortages in general and shortages of CASCAs specifically result in increased medication errors, delayed administration of life-saving therapy, inferior outcomes, and patient deaths. One way to mitigate drug shortages is to adopt an essential medicines list and ensure that these medications remain in adequate supply at all times. We argue for creation of a CASCA-specific essential medicines list for childhood cancer and provide ethical and policy-based reasoning for this approach. We recognize that such a call has implications beyond pediatric cancer, in that children with other serious disease should have an equal claim to access to guaranteed evidence-based medicines. We provide these arguments as an example of what should be claimed for medical indications that are deemed essential to preserve life and function.

Add or change institution